Follow us on Facebook!
Follow us on Twitter!
Follow us on Youtube!

Recent news

News archive

A website survey where doctors, patients and healthcare professionals can report unavailability of medicines has been developed.

Over the course of (at least) the following months, these reports will be collected and analysed so that we can develop a coherent picture of the scope, causes and consequences of these problems in Europe. At the moment such an overview does not exist which makes it difficult for European politicians and policy makers to take measures that are effective have high impact. Continue reading

The Committee of Permanent Representatives (COREPER I) mandated the Lithuanian Presidency to enter into negotiations with the European Parliament and the Commission with the aim to reach an agreement at first reading on the Proposal for a Regulation on Clinical trials on medicinal products for human use, which aims to facilitate the conduct of clinical trials and thus increase their number in the EU, which could result in better treatment of patients. Continue reading

Amendments of the European Union (EU) pharmacovigilance legislation that were adopted in October 2012 came into force on Monday 28 October 2013. These changes, which cover various aspects of the legislation, aim to further strengthen the protection of patient health by increasing the ability of the European medicines network to take prompt and appropriate regulatory action.

Continue reading

Pomalidomide (Pomalidomide Celgene®) has been granted a licence for use in myeloma patients across Europe.
This decision by the European Commission follows the positive recommendation in May 2013 for pomalidomide by the Committee for Medicinal Products for Human Use (CHMP), within the European Medicines Agency (EMA). Continue reading

The European Commission granted a licence for the use of two new indications of Velcade® (bortezomib) in the treatment of myeloma. It has approved its use as an induction treatment for newly diagnosed patients prior to high-dose therapy and autologous stem cell transplantation and as a retreatment in relapsed myeloma patients (in combination with thalidomide and dexamethasone) who have previously responded well to Velcade®. Continue reading

Statistically significant improvement in progression-free survival demonstrated

On Thursday 11 July 2013, Celgene International Sàrl announced that its phase III study (MM-020/IFM 07-01) of REVLIMID® (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival (PFS). In the study, a doublet regimen of continuous oral lenalidomide in combination with low-dose dexamethasone (Rd) demonstrated a statistically significant improvement in PFS compared to patients receiving a comparator arm with a triplet regimen consisting of melphalan, prednisone and thalidomide (MPT). Continue reading

We are delighted to anounce that the MPE report on Myeloma Patient Perspectives is being launched today, Friday 14 June 2013.
Printed copies are available at EHA 2013 in Stockholm.
Please feel free to pick up a copy at the EHA MPE booth (table top C14:11) from 14-16 June 2013.
For more information on these report, please send an email to info@myelomapatientseurope.org

MPE will be represented by several delegates at the 18th EHA congress in Stockholm (13-16 June 2013).
We also have a booth where printed versions of our key documents and recent publications will be provided, such as the MPE report on Myeloma Patient Perspectives, the executive summary of the report, a summary of our strategic plan 2013-2018 and the Clinical Trial Charter developed by MPE. Continue reading